These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9009311)

  • 21. Tetanus toxin fragment C-specific priming by intranasal infection with recombinant Bordetella pertussis.
    Reveneau N; Alonso S; Jacob-Dubuisson F; Mercenier A; Locht C
    Vaccine; 2001 Dec; 20(5-6):926-33. PubMed ID: 11738759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of cytotoxic T-cell activity by the protective antigen of Schistosoma mansoni Sm28GST or its derived C-terminal lipopeptide.
    Pancré V; Gras-Masse H; Delanoye A; Herno J; Capron A; Auriault C
    Scand J Immunol; 1996 Nov; 44(5):485-92. PubMed ID: 8947600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fasciola gigantica and Schistosoma mansoni: vaccine potential of recombinant glutathione S-transferase (rFgGST26) against infections in mice.
    Preyavichyapugdee N; Sahaphong S; Riengrojpitak S; Grams R; Viyanant V; Sobhon P
    Exp Parasitol; 2008 Jun; 119(2):229-37. PubMed ID: 18329021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunization with Schistosoma mansoni 22.6 kDa antigen induces partial protection against experimental infection in a recombinant protein form but not as DNA vaccine.
    Pacífico LG; Fonseca CT; Chiari L; Oliveira SC
    Immunobiology; 2006; 211(1-2):97-104. PubMed ID: 16446174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of protective efficacy induced by different heterologous prime-boost strategies encoding triosephosphate isomerase against Schistosoma japonicum in mice.
    Dai Y; Zhao S; Tang J; Xing Y; Qu G; Dai J; Jin X; Wang X
    Parasit Vectors; 2017 Feb; 10(1):111. PubMed ID: 28241779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective effect of rSm28GST-specific T cells in schistosomiasis: role of gamma interferon.
    Pancre V; Wolowczuk I; Guerret S; Copin MC; Delanoye A; Capron A; Auriault C
    Infect Immun; 1994 Sep; 62(9):3723-30. PubMed ID: 8063386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers.
    Berstad AKH; Holst J; Frøholm LO; Haugen IL; Wedege E; Oftung F; Haneberg B
    J Med Microbiol; 2000 Feb; 49(2):157-163. PubMed ID: 10670566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni.
    Ben-Yedidia T; Tarrab-Hazdai R; Schechtman D; Arnon R
    Infect Immun; 1999 Sep; 67(9):4360-6. PubMed ID: 10456875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum.
    Grangette C; Müller-Alouf H; Goudercourt D; Geoffroy MC; Turneer M; Mercenier A
    Infect Immun; 2001 Mar; 69(3):1547-53. PubMed ID: 11179325
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice.
    Jabbal-Gill I; Fisher AN; Rappuoli R; Davis SS; Illum L
    Vaccine; 1998 Dec; 16(20):2039-46. PubMed ID: 9796062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-cell immune response assessment as a complement to serology and intranasal protection assays in determining the protective immunity induced by acellular pertussis vaccines in mice.
    Ausiello CM; Lande R; Stefanelli P; Fazio C; Fedele G; Palazzo R; Urbani F; Mastrantonio P
    Clin Diagn Lab Immunol; 2003 Jul; 10(4):637-42. PubMed ID: 12853397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of a Schistosoma mansoni 28-kilodalton glutathione S-transferase in the livers of transgenic mice and its effect on parasite infection.
    Xu X; Lemaire C; Grzych JM; Pierce RJ; Raccurt M; Mullier F; Zerimech F; Decavel JP; Peyrol S; Liu J; Fontaine J; Lafitte S; Capron A; Cesbron JY
    Infect Immun; 1997 Sep; 65(9):3867-74. PubMed ID: 9284165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Construction and preliminary immunobiological characterization of a novel, non-reverting, intranasal live attenuated whooping cough vaccine candidate.
    Cornford-Nairns R; Daggard G; Mukkur T
    J Microbiol Biotechnol; 2012 Jun; 22(6):856-65. PubMed ID: 22573165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucosal and systemic immune responses elicited by recombinant Lactococcus lactis expressing a fusion protein composed of pertussis toxin and filamentous hemagglutinin from Bordetella pertussis.
    Torkashvand A; Bahrami F; Adib M; Ajdary S
    Microb Pathog; 2018 Jul; 120():155-160. PubMed ID: 29738814
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Morais SB; Figueiredo BC; Assis NRG; Homan J; Mambelli FS; Bicalho RM; Souza C; Martins VP; Pinheiro CS; Oliveira SC
    Front Immunol; 2018; 9():1762. PubMed ID: 30105029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection.
    Brown TH; David J; Acosta-Ramirez E; Moore JM; Lee S; Zhong G; Hancock RE; Xing Z; Halperin SA; Wang J
    Vaccine; 2012 Jan; 30(2):350-60. PubMed ID: 22075089
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Najminejad H; Kalantar SM; Mokarram AR; Dabaghian M; Abdollahpour-Alitappeh M; Ebrahimi SM; Tebianian M; Fasihi Ramandi M; Sheikhha MH
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):2605-2611. PubMed ID: 31240957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the nature of adjuvant and site of parenteral immunization on the serum and mucosal immune responses induced by a nasal boost with a vaccine alone.
    Guy B; Fourage S; Hessler C; Sanchez V; Millet MJ
    Clin Diagn Lab Immunol; 1998 Sep; 5(5):732-6. PubMed ID: 9729544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model.
    Cazorla SI; Frank FM; Becker PD; Corral RS; Guzmán CA; Malchiodi EL
    Vaccine; 2008 Apr; 26(16):1999-2009. PubMed ID: 18342408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules.
    Eo SK; Gierynska M; Kamar AA; Rouse BT
    J Immunol; 2001 May; 166(9):5473-9. PubMed ID: 11313385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.